Multiple sclerosis (MS), a chronic inflammatory and demyelinating disease of the central nervous system (CNS), is a major clinical and societal problem, which has a tremendous impact on the life of patients and their proxies. Current immunomodulatory and anti-inflammatory therapies prove to be relatively effective; however, they fail to concomitantly stop ongoing neurological deterioration and do not reverse acquired disability. The proportion to which genetic and environmental factors contribute to the etiology of MS is still incompletely understood; however, a recent association between MS etiology and obesity was shown, with obesity greatly increasing the risk of developing MS. An altered balance of adipokines, which are white adipose tissue (WAT) hormones, plays an important role in the low-grade chronic inflammation during obesity by their pervasive modification of local and systemic inflammation. Vice versa, inflammatory factors secreted by immune cells affect adipokine function. To explore the role of adipokines in MS pathology, we will here review the reciprocal effects of adipokines and immune cells and summarize alterations in adipokine levels in MS patient cohorts. Finally, we will discuss proof-of-concept studies demonstrating the therapeutic potential of adipokines to target both neuroinflammation and neurodegeneration processes in MS.
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system (CNS) characterized by the presence of focal demyelinated plaques. Sufficient clearance of myelin and cellular debris is one of the requirements for proper tissue repair and remyelination. The mechanisms underlying the clearance of such debris by phagocytes are not fully understood, but recent findings suggest a prominent role for lipoprotein-lipase (LPL) in this process. Here, we demonstrate that angiopoietin-like 4 (ANGPTL4), a potent inhibitor of LPL, is abundantly expressed in astrocytes in control white matter tissue and its expression is markedly reduced in active MS lesions. We provide evidence that ANGPTL4 inhibits the uptake of myelin-derived lipids by LPL-immunoreactive phagocytes. Taken together, our data suggest that the strong reduction in astrocytic ANGPTL4 expression in active demyelinating MS lesions enables phagocytes to adequately clear myelin debris, setting the stage for remyelination.
19 July 2025 in Multiple Sclerosis and Related Disorders
Grey matter (GM) lesions and atrophy in multiple sclerosis (MS) are strongly correlated to disease progression and cognitive decline, but molecular mechanisms underlying GM lesion formation remain unclear. Various studies have used a proteomics approach to study changes in cerebrospinal fluid or blood. However, very few studies have been performed in tissue and especially GM lesions are understudied, despite the importance of these lesions in disease progression. For this explorative study, we applied Olink proteomics to unravel differentially expressed proteins in the GM of MS patients (n = 9) compared to controls (n = 10). First, we evaluated which of the 184 proteins in a neurology and inflammation panel could accurately distinguish MS from control by applying a classifier based on unbiased variable selection. The classifier consisted of five proteins: HGF, PVR, NEP, EFNA4 and LAP.TGF.beta1. These were all differentially expressed in GMLs of MS patients (FDR < 0.1), amongst twelve others. Additionally, we studied proteomic changes between MS cases with different GM lesion loads and identified IL-20, CD5 and GZMA to distinguish large from small lesions. Eight other proteins were nominally differentially expressed based on lesion load. Future studies should explore the potential of targeting these proteins to hamper grey matter pathology.